Mode
Text Size
Log in / Sign up
Phase 2 N=9 Randomized Single-blind Treatment

Chemoradiation or Brachytherapy for Rectal Cancer

Rectal Cancer

Enrolled (actual)
9
Serious AEs
33.3%
Results posted
Feb 2023
Primary outcome: Primary: Number of Patients With Pathologic Complete Response — 0; 2 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Endo-HDR (if randomized to this arm) (Radiation); capecitabine and IMRT (if randomized to this arm) (Drug); IMRT (intensity modulated radiation therapy) (Radiation); FOLFOX6 (Drug); Surgery (Procedure)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Primary completion
Sep 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Patients With Pathologic Complete Response
0; 2
SECONDARY
Number of Participants With Grade 3 or Higher Adverse Events
1; 1; 1; 1; 1; 0
SECONDARY
Change in EORTC QLQ-C30 Global Health Status Score
83; 71.2; 33; 49.6; 54; 72.5
SECONDARY
Time to Death
SECONDARY
Time to Distant Metastases Free Survival
SECONDARY
Time to Progression Free Survival
SECONDARY
Time to Local Disease Recurrence

Summary

This research is being done to compare the effectiveness of high dose endorectal brachytherapy (END-HDR) and the standard treatment option of chemoradiation with Capecitabine in the treatment of cancer of the lowest part of the bowel (rectum).

Eligibility Criteria

Inclusion Criteria

  • Confirmed adenocarcinoma of the rectum
  • Appropriate tumor staging and location
  • Patients should be suitable candidates for surgery and chemotherapy
  • ECOG/WHO performance status 0-1
  • Patients must be 18 years or older
  • No previous history of pelvic radiation
  • Patients must have acceptable organ and marrow function
  • Non pregnant, non-breast feeding females under active contraception
  • Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria

  • Evidence of distant metastatic disease
  • Evidence of sphincter invasion on MRI
  • Prior history of radiation to the pelvis
  • Prior malignancy except for adequately treated basal cell or squamous cell skin cancer, cervical carcinoma in situ, DCIS, or other cancer from which the patient has been disease free for at least 3 years
  • Presence of multiple small bowel loops trapped within the immediate tumor bed (post hysterectomy or prostatectomy).
  • Use of any investigational agent within the 4 weeks preceding enrollment
  • Previous exposure to chemotherapy for rectal cancer
  • Uncontrolled intercurrent illness including but not limited to, ongoing or active infections (or infections requiring systemic treatment), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant and breastfeeding women are excluded, as well as women of child-bearing potential who are unwilling or unable to use an acceptable method of birth control (hormonal or barrier method of birth control; abstinence) to avoid pregnancy for the duration of the study. Should a woman become pregnant or suspect she is pregnant while participating in this study she should inform her treating physician immediately.
  • Women who are not post-menopausal and have a positive urine or serum pregnancy test or refuse to take a pregnancy test.
  • Contraindication for safe MRI, implants, or other conditions that interfere with imaging required for the study (e.g., pacemaker or non-MRI compatible hip prostheses). Note: Subjects with bilateral hip implants are not eligible for the study. Subjects with a unilateral hip implant may be eligible assuming the implant is MRI compatible and does not present artifact on MRI in the areas of interest.
  • Subject is pacemaker dependent.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02017704). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search